



Dupilumab Reduces Itch In Children With Moderate-To-Severe Atopic Dermatitis Aged 6 Months To 5 Years

Paller A^{1,2}, Siegfried E^{3,4}, Yosipovitch G⁵, Kwatra S⁶, Praestgaard A⁷, Prescilla R⁷, Wang Z⁸

¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ²Ann and Robert H. Lurie Children’s Hospital, Chicago, IL, USA; ³Saint Louis University, St. Louis, MO, USA; ⁴Cardinal Glennon Children’s Hospital, St. Louis, MO, USA; ⁵University of Miami, Miami, FL, USA; ⁶Johns Hopkins University School of Medicine, Baltimore, MD, USA; ⁷Sanofi, Cambridge, MA, USA; ⁸Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

BACKGROUND

- Atopic dermatitis (AD) is a common chronic inflammatory skin condition hallmarked by pruritus, disruption of skin-barrier function, and type 2 immune dysregulation, that begins before age 5 in over 85% of patients¹
- Intense pruritus is considered the most burdensome symptom of AD, and has a negative impact on the patient’s quality of life, sleep, and mental health²
- Dupilumab treatment led to sustained reduction of itch in phase 3 studies involving adults, adolescents, and children above 6 years of age with AD, with an acceptable safety profile^{3–5}

OBJECTIVE

- To report the impact of dupilumab treatment on itch in children aged 6 months to 5 years with moderate-to-severe AD

METHODS

- This analysis reports pruritus parameters from patients aged 6 months to 5 years with moderate-to-severe AD, inadequately controlled with topical corticosteroids (TCS). These results were obtained during the double-blind, placebo-controlled, phase 3 study: LIBERTY AD PRESCHOOL (NCT03346434 part B)
- Patients were treated with:
 - Dupilumab subcutaneously every 4 weeks (q4w) + TCS (n = 83)
 - Baseline weight ≥ 5 kg to < 15 kg: 200 mg
 - Baseline weight ≥ 15 kg to < 30 kg: 300 mg
 - Placebo + TCS (n = 79)
- Impact on pruritus was assessed through:
 - Clinician-assessed SCORing Atopic Dermatitis Pruritus Visual Analog Scale (SCORAD Pruritus VAS; 0–10)
 - Caregiver-reported Worst Scratch/Itch Score Numeric Rating Scale (WSI-NRS; 0–10)
 - Proportion of caregivers reporting the number of days with itchy skin over the previous 7 days by visit on behalf of the patient – Patient-Oriented Eczema Measure Itch item (POEM Itch item)

RESULTS

Figure 1. Mean percentage change from baseline (± SE) in SCORAD Pruritus VAS at each visit from baseline to Week 16.^a





Figure 2. LS mean percentage change from baseline (± SE) in weekly average of daily Worst Scratch/Itch NRS score at each visit through Week 16.^a



SAFETY

- Overall safety was consistent with the known dupilumab safety profile

Figure 3. Proportion of patients with ≥ 4-point improvement from baseline in weekly average of Worst Scratch/Itch NRS score at each visit through Week 16.





Figure 4. Proportion of caregivers reporting the number of days with itchy skin over the previous week, on behalf of the patient, by visit (POEM Itch item).



CONCLUSION

- Dupilumab treatment leads to rapid and sustained improvements in itch intensity and duration in children aged 6 months to 5 years with moderate-to-severe AD

References: 1. Pyun BY. Allergy Asthma Immunol Res. 2015;7:101–5. 2. Legat FJ. Front Med. 2021;8:1–11. 3. Simpson EL, et al. N Engl J Med. 2016;375:2335–48. 4. Simpson EL, et al. JAMA Dermatol. 2020;156:44–56. 5. Paller AS, et al. J Am Acad Dermatol. 2020;83:1282–93.

Acknowledgments: Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifiers: NCT03346434 part B. Rainbow graphs developed by Ana B. Rossi and Marthe Vuillet of Sanofi. Medical writing/editorial assistance was provided by Benjamin Danet, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.

Disclosures: **Paller AS:** AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, LEO Pharma, UCB – investigator; Amryt Pharma, Azitra, BioCryst, BMS, Boehringer Ingelheim, Castle Creek Biosciences, Eli Lilly, Janssen, Krystal Biotech, LEO Pharma, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Seanergy, TWI Biotechnology, UCB – consultant; AbbVie, Abeona Therapeutics, Catawba Research, Galderma, InMed Pharmaceuticals – data and safety monitoring board. **Siegfried EC:** Dermavant, Eli Lilly, Pfizer, Regeneron Pharmaceuticals Inc., Verrica Pharmaceuticals – consultant; GSK, LEO Pharma, Novan – data and safety monitoring board; Eli Lilly, Janssen, Regeneron Pharmaceuticals Inc., Stiefel, Verrica Pharmaceuticals – Principal Investigator in clinical trials. **Yosipovitch G:** Arcutis Antibiox, Bellus Health, Eli Lilly, Galderma, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Trevi Therapeutics – advisory board member; Eli Lilly, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer – grants/research funding; Regeneron Pharmaceuticals Inc., Sanofi – investigator. **Kwatra SG:** AbbVie, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte, Johnson & Johnson, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi – advisory board member/consultant; Galderma, Incyte, Pfizer, Sanofi – investigator. **Praestgaard A, Prescilla R:** Sanofi – employees, may hold stock and/or stock options in the company. **Wang Z:** Regeneron Pharmaceuticals Inc. – employee and shareholder.

Presented at the 2023 Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Inc (ISPOR); Boston, MA, USA; May 7–10, 2023.